MedTrace Logo

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

NCT04082936 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2024-07-24

No results posted yet for this study

Summary

This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This study will consist of a dose-escalation stage, a combination stage, and a randomized dose-expansion stage where subjects will be enrolled into indication-specific expansion cohorts. imvotamab will be administered intravenously (IV).

Additional CD20-positive NHL histologies (e.g. MZL and MCL), may be allowed with Medical Monitor approval during the Dose-Escalation Phase of the study.

Conditions

Interventions

DRUG

imvotamab

Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.

Sponsors & Collaborators

  • ADC Therapeutics S.A.

    collaborator INDUSTRY

  • IGM Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • IGM Biosciences · IGM Biosciences, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-30
Primary Completion
2024-02-16
Completion
2024-02-22
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Czechia
  • France
  • Italy
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04082936 on ClinicalTrials.gov